drugset / Trial / NCT04734210

Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease

NCT04734210

Phase 2 Completed 139 enrolled Surface Ophthalmics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

SURF-200 is being studied in people experiencing an episodic flare-up of their dry eye disease. SURF-200 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop. The purpose of this research study is to see how well SURF-200 works and what side effects there are, and to compare it with vehicle (placebo). The study will involve about 120 study participants at multiple research sites in the United States.

Timeline

Start
2021-01-07
Primary completion
2022-10-12
Completion
2022-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Betamethasone Other / unclassified 0.02 % Topical
Subject Betamethasone Other / unclassified 0.04 % Topical

Indications